UK-based orthobiologics company Locate Bio has secured £9.2m in an oversubscribed funding round, aimed at advancing a clinical study of its LDGraft product. The funding will facilitate the Randomised Study of LDGraft in Single Level Anterior Lumbar Interbody Fusion (RESTORE), the next step in the company’s commitment to improving orthopaedic patient outcomes. Source: Medical Device Network 29/4/2024